Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan
Cancer Science · 2026
DOI: 10.1111/cas.70411 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Science, 2026. Verfasst von Junichi Shimizu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Pivotal phase 3 trials leading to the approvals of atezolizumab─chemotherapy combinations for non‐small cell and extensive‐stage small cell lung cancer (NSCLC and ES‐SCLC) had strict eligibility criteria. J‐TAIL‐2 was a prospective, observational study in Japan that evaluated atezolizumab regimens for advanced NSCLC/ES‐SCLC, including patients ineligible for global trials. The primary endpoint was 12‐month overall survival (OS); safety and efficacy in subgroups defined by age, ECOG PS and/or G8 score, and creatinine clearance were key secondary endpoints. As of February 3, 2023, 1217 patients were treated in clinical practice based on Japanese labeling/treatment guidelines. Patients received atezolizumab with either carboplatin and nab‐paclitaxel (atezo + CnP), carboplatin/cisplatin and pemetrexed (atezo + PP), or bevacizumab and carboplatin and paclitaxel (atezo + bev + CP) in the NSCLC cohort ( n = 814) or with carboplatin and etoposide (atezo + CE) in the ES‐SCLC cohort ( n = 403). Overall, 53.5% were ≥ 70 years old, and 11.8% had ECOG PS ≥ 2; median G8 scores were 13 (NSCLC cohort) and 12 (ES‐SCLC). Patients < 70 and ≥ 70 years had similar median (m)OS and progression‐free survival (mPFS) across treatment regimens. Patients with ECOG PS < 2 and G8 score ≥ median had the highest mOS/PFS vs. patients with ECOG PS ≥ 2 and G8 score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
ORCID-Profile: Makoto Nishio, Kadoaki Ohashi, Eiki Kikuchi, Yasushi Goto, Hiroshige Yoshioka, Akihiko Gemma
Förderung
- Chugai Pharmaceutical
Zitieren
APA
Shimizu, J., Nishio, M., Ohashi, K., Osoegawa, A., Kikuchi, E., Kimura, H., Goto, Y., Miyauchi, E., Yoshioka, H., Yoshino, I., Misumi, T., Yoshimori, K., Shibata, K., Tsuda, T., Seike, M., Ota, T., Samata, K., Kobayashi, Y., Tanaka, M., & Gemma, A. (2026). Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan. Cancer Science. https://doi.org/10.1111/cas.70411
Vancouver
Shimizu J, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, et al. Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan. Cancer Science. 2026. doi:10.1111/cas.70411
BibTeX
@article{Shimizu2026,
author = {Shimizu, Junichi and Nishio, Makoto and Ohashi, Kadoaki and Osoegawa, Atsushi and Kikuchi, Eiki and Kimura, Hideharu and Goto, Yasushi and Miyauchi, Eisaku and Yoshioka, Hiroshige and Yoshino, Ichiro and Misumi, Toshihiro and Yoshimori, Kozo and Shibata, Kazuhiko and Tsuda, Takeshi and Seike, Masahiro and Ota, Takahiro and Samata, Koichi and Kobayashi, Yuki and Tanaka, Misa and Gemma, Akihiko},
title = {Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70411}
}
EUVIMED